As one of the three leading industries in Shanghai, what is the current scale of the industry? In what areas will we focus our efforts in the future? In response to these topics of concern to the outside world, Jincheng Wu, director of the Shanghai Municipal Commission of Economy and Information Technology, responded at the municipal government’s press conference on the 26th.
Wu said that Shanghai is currently based on the development of the biopharmaceutical industry, focusing on breakthroughs in advantageous fields, leading innovation and development of key areas, construction of industrial environments, building leading enterprises, and speeding up the establishment of a industry process chain of “R&D + clinical + manufacturing + application.” Shanghai is also focused on continuing to improve the spatial layout of the “1+5+X” biopharmaceutical industry, take multiple measures to promote the “Zhangjiang R&D + Shanghai Manufacturing”, and achieve new breakthroughs in the industrial scale.
In 2020, the scale of Shanghai’s biopharmaceutical industry exceeded 600 billion yuan, a record high of which the output value of the manufacturing industry reached 140 billion yuan, a comparable increase of 2.9%. This year, the growth momentum of biomedicine has not diminished. In the first half of the year, the scale of the industry has exceeded 350 billion yuan, an increase of 22.8%; 3 new local sci-tech innovation board listed companies have been added, reaching 15 in total.
Wu said that during the “14th Five-Year Plan” period, Shanghai will grasp the general direction and trend of the booming global bio-economy, cultivate and expand the biomedical industry cluster, and continue to exert efforts in three aspects.
One is to speed up research on core technologies. It is important to strengthen research and industrialization breakthroughs in innovative drugs, high-end medical devices, high-end preparations, advanced technology, and urgently needed medical materials for public health. It’s also necessary to support enterprises to cooperate with universities, scientific research institutes, and medical institutions to carry out high-quality collaborative innovation. For example, in the field of biopharmaceuticals, in order to open up the upstream and downstream of the industrial chain, coordination and cooperation must be strengthened, the establishment of the “Biopharmaceutical Industry Innovation Alliance” must be established, and a stronger industrial chain must be promoted.
The second is to strengthen the layout in frontier fields. This involves maintaining and giving play to the city’s leading advantages in antibody drugs, cell therapy, gene therapy and other fields, carrying out a forward-looking layout, and continuing to promote the innovative layout of basic research and applied basic research around brain science, stem cell and regenerative medicine and other cutting-edge and basic fields. The goal is to accelerate the establishment of an innovative highland for the biomedical industry with global influence.
The third is to accelerate the transformation of innovation achievements. This is led by “Zhangjiang R&D + Shanghai Manufacturing” and relies on the “1+5+X” industrial space layout. There needs to be a strengthening in cross-regional linkage and overall planning, more encouragement for various parks to innovate and coordinate models in order to effectively improve the carrying capacity of Shanghai’s biomedical projects. This will also guide and support the transformation and industrialization of local, national and even global biomedical innovations in Shanghai.
The goal is to strive to achieve a scale of 1.2 trillion yuan in the city’s biomedicine industry by 2025, of which the output value of the manufacturing industry will reach 280 billion yuan and to achieve independent controllability of several key core technologies with remarkable results in the industrialization of innovation.
To achieve the above goals, Shanghai will continue to make efforts in policy. Wu said that Shanghai has comprehensive advantages that other regions and cities in China cannot match in the development of the biomedical industry. This includes urban branding, policy support, integration of industry and medicine, service ecology, and financial supply.
Especially in terms of policy support, the “Several Opinions of Shanghai Municipality on Promoting the High-quality Development of the Biomedical Industry” was issued in April this year, covering the entire industry policy system of “R&D + clinical + manufacturing + application” and clarifying the future of the biomedical industry. Shanghai is also promoting the facilitation of customs clearance for R&D items and special items and establishing a “whitelist” of biomedical pilot companies and items. Shanghai is simplifying the pre-approval procedures for related items in the list and facilitating customs clearance, etc., to further develop biomedical companies.
In addition to municipal policies, many districts and parks have issued their own corresponding supporting policies. For example, Lingang Special Area supports up to 100 million yuan in investment in major strategic emerging industry projects. Companies engaged in biomedicine core technology businesses are levied 15% corporate income tax within 5 years. The Pudong New Area gives up to 50 million yuan for new high-quality industrial projects. Fengxian, Jinshan, Baoshan, Minhang and other districts have given special support to R&D innovation and industrialization projects.